drugset
drugset / Trial / NCT00009698

Interleukin-2 in Treating Children Who Have Undergone Bone Marrow Transplantation for Acute Myeloid Leukemia

NCT00009698 ↗

Phase 1 Completed 1 enrolled Children's Oncology Group National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill more cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating children who have undergone bone marrow transplantation for acute myeloid leukemia.

Timeline

Start
1998-03
Primary completion
2001-06
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic 1e+06 unknown Subcutaneous

Indications

leukemia